SCHEMBL769700

SCHEMBL769700

O=C(CCCC(=O)N1CCCC2CCCCC21)NC1c2ccccc2-c2ccccc21

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TSHR P16473 2/20 0.43
HSD11B1 P28845 3/20 0.41
HPGD P15428 2/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPK1 P28482 1/20 0.40
DRD2 P14416 1/20 0.39
DRD4 P21917 1/20 0.39
KMT2A Q03164 2/20 0.39
F2 P00734 2/20 0.38
HSD17B1 P14061 1/20 0.38
MEN1 O00255 1/20 0.38
DPP4 P27487 1/20 0.38
KCNH2 Q12809 1/20 0.37
PDE3B Q13370 1/20 0.37
PDE3A Q14432 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770314 0.82 TSHR (0.49) SMN1; SMN2TSHRHPGDALDH1A1DRD2
SCHEMBL770547 0.82 KCNH2 (0.41) NPC1RAB9ASMN1; SMN2HPGDALDH1A1
SCHEMBL771304 0.81 TSHR (0.56) MAPTSMN1; SMN2TSHRHPGDALDH1A1
SCHEMBL770313 0.81 MAPT (0.54) MAPTNPC1RAB9ASMN1; SMN2HSD11B1
SCHEMBL770594 0.80 CYP2D6 (0.43) NPC1RAB9ASMN1; SMN2HSD11B1DRD2
SCHEMBL771390 0.78 SMN1; SMN2 (0.53) SMN1; SMN2HPGDALDH1A1MAPK1KMT2A
SCHEMBL772428 0.78 SMN1; SMN2 (0.53) SMN1; SMN2HPGDALDH1A1MAPK1KMT2A
SCHEMBL770615 0.78 DRD2 (0.49) NPC1RAB9ASMN1; SMN2HSD11B1DRD2
SCHEMBL770291 0.77 GAA (0.56) NPC1RAB9ASMN1; SMN2HSD11B1ALDH1A1
SCHEMBL7265245 0.77 MAPT (0.47) MAPTTSHRKMT2AF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2439202-B1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 SALVAT LAB SA (ES) 2016-04-20 EP disclosed
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 MAPT 618/4885NPC1 97/4885RAB9A 2187/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 MAPT 638/4885NPC1 104/4885RAB9A 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.